Central Trust Company’s Generation Bio GBIO Stock Holding History

Central Trust Company’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5	Closed	-$1K	–	1212
2021 Q1	$1K	Buy	+5	New	+$1.6K	﹤0.01%	1097

Other funds holding GBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Central Trust Company's GBIO Position: Q2 2021 in Review

Central Trust Company sold out of Generation Bio (GBIO) in Q2 2021, closing a stake of 5 shares — an estimated $1K sold.

Central Trust Company first reported a position in GBIO in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 97 funds tracked by Wall St. Rank hold GBIO as of Q2 2021.

Central Trust Company reported no remaining Generation Bio position as of Q2 2021 after selling out during the quarter.
Central Trust Company sold 5 Generation Bio shares in Q2 2021, an estimated $1K.
Central Trust Company first reported a position in Generation Bio in Q1 2021 and held it in 1 quarter.
Central Trust Company's Generation Bio position peaked at $1K in Q1 2021.
97 funds tracked by Wall St. Rank held Generation Bio as of Q2 2021.

Based on Central Trust Company's 13F filing for Q2 2021, filed 23 Jul 2021.